{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:52:28Z","timestamp":1771332748548,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.neuropharm.2013.10.015","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:25:36Z","timestamp":1382660736000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications"],"prefix":"10.1016","volume":"77","author":[{"given":"Subramaniam","family":"Uthayathas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunasingh J.","family":"Masilamoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-9534","authenticated-orcid":false,"given":"Frank S.","family":"Menniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella M.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.10.015_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib2","first-page":"1519","article-title":"Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study","volume":"45","author":"Boellaard","year":"2004","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.107.125666","article-title":"Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys","volume":"323","author":"Cao","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib4","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/sj.npp.1301362","article-title":"Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy","volume":"32","author":"Capuron","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib5","first-page":"458","article-title":"PDE10A inhibitors: an assessment of the current CNS drug discovery landscape","volume":"12","author":"Chappie","year":"2009","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib6","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1021\/jm3004976","article-title":"Current landscape of phosphodiesterase 10A (PDE10A) inhibition","volume":"55","author":"Chappie","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbr.2008.09.029","article-title":"Neurocomputational models of basal ganglia function in learning, memory and choice","volume":"199","author":"Cohen","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11846","article-title":"Concurrent activation of striatal direct and indirect pathways during action initiation","volume":"494","author":"Cui","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib10","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1016\/j.bmcl.2012.07.007","article-title":"Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia","volume":"22","author":"Cutshall","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib12","series-title":"Society for Biological Psychiatry 2012 Annual Meeting","first-page":"17S","article-title":"Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of Schizophrenia","author":"DeMartinis","year":"2012"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0166-2236(92)90355-C","article-title":"The neostriatal mosaic: multiple levels of compartmental organization","volume":"15","author":"Gerfen","year":"1992","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.conb.2005.10.006","article-title":"The basal ganglia: learning new tricks and loving it","volume":"15","author":"Graybiel","year":"2005","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchemneu.2003.10.003","article-title":"The primate basal ganglia: parallel and integrative networks","volume":"26","author":"Haber","year":"2003","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11682-010-9100-5","article-title":"Acute brain metabolic effects of cocaine in rhesus monkeys with a history of cocaine use","volume":"4","author":"Henry","year":"2010","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib19","series-title":"Guide for the Care and Use of Laboratory Animals","author":"ILAR","year":"1996"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1353-8020(02)00115-3","article-title":"The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease","volume":"9","author":"Jenner","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0166-2236(95)98374-8","article-title":"Striatal interneurones: chemical, physiological and morphological characterization","volume":"18","author":"Kawaguchi","year":"1995","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/13543776.17.2.147","article-title":"The potential therapeutic use of phosphodiesterase 10 inhibitors","volume":"17","author":"Kehler","year":"2007","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib24","first-page":"40","article-title":"Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons","volume":"60","author":"Kitai","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.110.173294","article-title":"Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease","volume":"336","author":"Kleiman","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.neuro.051508.135422","article-title":"Physiology and pharmacology of striatal neurons","volume":"32","author":"Kreitzer","year":"2009","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/brain\/91.1.1","article-title":"The functional organization of the motor system in the monkey. I. The effects of bilateral pyramidal lesions","volume":"91","author":"Lawrence","year":"1968","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib30","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd2058","article-title":"Phosphodiesterases in the CNS: targets for drug development","volume":"5","author":"Menniti","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib32","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in\u00a0vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib33","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnana.2011.00043","article-title":"Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons","volume":"5","author":"Nishi","year":"2011","journal-title":"Front Neuroanat."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejphar.2008.02.005","article-title":"Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics","volume":"584","author":"Olsen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ana.20279","article-title":"Prolongation of levodopa responses by glycine(B) antagonists in parkinsonian primates","volume":"56","author":"Papa","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.nlm.2010.11.018","article-title":"Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-deficient mice suggest a role for striatal signaling in evaluative salience attribution","volume":"95","author":"Piccart","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","article-title":"Radiosynthesis and in\u00a0vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A","volume":"38","author":"Plisson","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnins.2011.00103","article-title":"Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms","volume":"5","author":"Roberds","year":"2011","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib42","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib43","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","article-title":"Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2","volume":"105","author":"Sano","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neuropharm.2007.10.009","article-title":"Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57\/B16N congenic background","volume":"54","author":"Siuciak","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib48","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1471-1931(00)00023-9","article-title":"Anatomy of the dopamine system in the basal ganglia","volume":"23","author":"Smith","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib49","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2009.09.008","article-title":"Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A","volume":"58","author":"Strick","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib51","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1523\/JNEUROSCI.16-20-06579.1996","article-title":"Coordinated expression of dopamine receptors in neostriatal medium spiny neurons","volume":"16","author":"Surmeier","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.tins.2004.08.007","article-title":"GABAergic microcircuits in the neostriatum","volume":"27","author":"Tepper","year":"2004","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneumeth.2013.02.004","article-title":"Assessment of adverse effects of neurotropic drugs in monkeys with the \u201cDrug Effects on the Nervous System\u201d (DENS) scale","volume":"215","author":"Uthayathas","year":"2013","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib55","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm900521k","article-title":"Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of Schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00213-008-1419-x","article-title":"Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine","volume":"203","author":"Weber","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib57","first-page":"53","article-title":"Electrophysiological interactions between striatal glutamatergic and dopaminergic systems","volume":"1003","author":"West","year":"2003","journal-title":"Glutamate Disord. Cogn. Motiv."},{"key":"10.1016\/j.neuropharm.2013.10.015_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/cercor\/9.3.264","article-title":"Representational plasticity in cortical area 3b paralleling tactual-motor skill acquisition in adult monkeys","volume":"9","author":"Xerri","year":"1999","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2013.10.015_bib59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T04:48:09Z","timestamp":1564548489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813004917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":59,"alternative-id":["S0028390813004917"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.015","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}